CCH Holdings Plans to Acquire Three Malaysia-Based Restaurant Groups in 2026
CCH Holdings issued further details on a series of anticipated acquisitions, new business ventures, and international expansion planned for 2026. These developments include the following: Acquisition of three Malaysia-based restaurant groups, including three additional outlets of the Sichuan cuisine franchise, Banbudian Bistro; thirteen outlets of Chao Liu Xian Hotpot, a restaurant chain offering Chaoshan-style dishes; and four franchised outlets of the Chicken Claypot House chain that were not part of the group that listed as CCH Holdings on Nasdaq in October 2025. These acquisitions are expected to close in the first half of 2026. Opening of a New York City Chicken Claypot House restaurant in midtown Manhattan in the second half of the year. Establishment of an Africa-based factory to produce instant noodles and sauce for local distribution as well as to Europe and the U.S., to open in H2 2026. Introduction of a new hotpot restaurant brand, Foong Hotpot & Bistro, during the first quarter of 2026, as well as the opening of a new bakery shop, 6 Mil Bakery, in the first half of next year. Both businesses will be located in Johor Bahru, Malaysia. The company intends to fund all the above investments via its existing cash resources.
Get Free Real-Time Notifications for Any Stock
Analyst Views on CCHH
About CCHH
About the author
Rapt Therapeutics Acquired by GSK for $58 per Share, Valuing at $2.2 Billion
- Acquisition Deal: GSK has agreed to acquire Rapt Therapeutics for $58 per share, representing an estimated total equity value of $2.2 billion, which will significantly enhance GSK's market position in the biopharmaceutical sector.
- Stock Surge: Rapt Therapeutics' shares jumped 63.4% to $57.36 in pre-market trading, reflecting a positive market reaction to the acquisition, which may attract more investor interest in the company.
- Market Impact: This acquisition not only increases shareholder value for Rapt but may also prompt other biotech firms to consider similar strategic acquisitions to enhance their competitiveness and market share.
- Industry Outlook: With GSK's acquisition, Rapt's product development process is expected to accelerate, potentially leading to faster drug launches and further solidifying GSK's leadership position in the innovative pharmaceuticals market.
CCH Holdings Completes IPO Over-Allotment, Raising $750,000
- Successful Financing: CCH Holdings Ltd's underwriters fully exercised the over-allotment option in its IPO, purchasing an additional 187,500 ordinary shares, raising $750,000, which strengthens the company's capital base for future initiatives.
- Increased Total Proceeds: Following the over-allotment, CCH Holdings sold a total of 1,437,500 ordinary shares in the IPO, increasing total proceeds to $5.75 million, providing robust funding support for future expansion and operations.
- Market Performance: CCH Holdings' ordinary shares began trading on the Nasdaq Capital Market on October 3, 2025, marking a successful entry into the capital markets, which is expected to enhance brand visibility and attract more investor interest.
- Strategic Development: This financing will enable CCH Holdings to further expand its specialty hotpot market presence in Malaysia and Southeast Asia, enhancing its competitive edge and driving business growth.
